Name | LY3200882 |
---|
Description | LY3200882 is a novel and highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). |
---|---|
Related Catalog | |
Target |
TGFβRI[1] |
In Vitro | LY3200882 is a novel, highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells. LY3200882 has shown anti-metastatic activity in vitro in migration assays. In in vitro immune suppression assays, LY3200882 has shown the ability to rescue TGFβ1 suppressed or T regulatory cell suppressed naïve T cell activity and restore proliferation[1]. |
In Vivo | LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose dependent fashion. LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer)[1]. |
References |
Molecular Formula | C24H29N5O3 |
---|---|
Molecular Weight | 435.52 |
Storage condition | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |